Focusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC Practices

By EClinCloud. Originally published on the "EClinCloud" WeChat Official Account on November 2, 2026.
On October 30, the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference was held in Suzhou. Zheng Liangyan, Medical Director at EClinCloud, delivered a keynote presentation titled "Pain Points and Solutions for Endpoint Assessment in Central Nervous System Disease Clinical Research," providing an in-depth discussion of key challenges, regulatory requirements, and practical implementation in CNS endpoint assessment, which drew attention and positive feedback from the audience.



01 Addressing Challenges in CNS Endpoint Assessment
Conditions such as Alzheimer's disease and Parkinson's disease are characterized by a long disease course, slow progression, and complex clinical manifestations; drug efficacy often requires comprehensive evaluation across multiple dimensions, including cognition, motor function, activities of daily living, and imaging.
Accordingly, accurately capturing clinical changes in patients and reducing subjective variability during assessment have become important factors affecting the quality of CNS clinical studies.
Drawing on the characteristics of CNS clinical research, the presentation noted that traditional assessment methods face three main challenges:
- Clinical scales rely heavily on rater experience, and fluctuations in patient status can also introduce scoring variability;
- Multicenter imaging acquisition standards are inconsistent and lack centralized quality control spanning both acquisition and reading;
- CNS studies typically require long-term follow-up, and factors such as frequent hospital visits for elderly patients and the complexity of paper-based scales can easily increase patient burden and affect compliance and data integrity.
These challenges are interconnected and ultimately point to the question of how to establish a more standardized, objective, and sustainable endpoint assessment system.
02 Safeguarding Reliability with eCOA and IRC
To address these issues, the presentation focused on approaches to applying eCOA and IRC.
Through electronic scales, standardized rater training, automated scoring, and logic checks, eCOA reduces manual operations and variability during assessment, while lowering barriers to patient participation through BYOD, customized devices, and remote data capture. IRC improves the consistency and comparability of multicenter imaging data through unified imaging acquisition standards, centralized imaging quality control, independent blinded reading, and adjudication mechanisms.
Together, the two improve the reliability of endpoint assessment from different dimensions and have been applied in EClinCloud's actual projects:
In studies of conditions such as Alzheimer's disease and post-stroke cognitive impairment, EClinCloud has supported the standardized administration of complex scales and improved patient compliance through electronic scales, rater training, customized rating devices, and central quality control;
In an Alzheimer's disease study covering 1000+ patients, EClinCloud further integrated eCOA and IRC solutions, providing multidimensional endpoint data support for the study through electronic scales and independent imaging assessment.
From practical study experience, endpoint assessment quality cannot be achieved by relying on a single tool alone; rather, it requires combining standardized processes, specialized assessment capabilities, and digital technologies across every stage of study execution.
Looking ahead, with advances in AI technologies, wearable devices, and remote data capture, the integration of clinical outcome data and imaging data will offer greater possibilities for evaluating the efficacy of CNS drugs. EClinCloud will continue to deepen its focus on the CNS field, centering on core capabilities such as eCOA and IRC to help improve endpoint assessment quality in clinical research.
About EClinCloud
EClinCloud is a leading AI company in the clinical research industry. Powered by AI, it builds an integrated intelligent clinical cloud platform and endpoint assessment technologies, providing global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as scale management, linguistic validation, rater training, and data quality analysis services to deliver efficient, precise digital solutions. Leveraging AI predictive models and an intelligent data platform, EClinCloud dynamically evaluates and helps improve drug clinical trial success rates, helping shorten drug and device development cycles for the benefit of patients.


